Table 1.

Tumor response criteria — WHO, RECIST 1.0 and RECIST 1.1 and classification of tumor assessment

WHO	RECIST 1.0	RECIST 1.1
No particular number of lesions specified	Requires 10 targets per five organs when measuring the tumor burden	Requires only five targets (two per organ).
Bi dimensionally measurable lesion; no stipulation of minimal size of the lesion	Measures the long axis of lymph nodes as for other lesions	Measures the short axis of lymph nodes and long axis for other lesions
50% decrease in target lesions, without a 25% increase in any one target lesion; confirmed at 4 wk	Defines progression as a 20% increase in sum	A 20% increase and at least 5 mm absolute increase.
	States that disease progression for non-measurable disease “must be unequivocal”	Expands that definition to convey an impact on the overall burden of disease.
	States that confirmation is required but in new version only if response is primary endpoint	Includes a new section that incorporates a comment on FDG PET interpretation